Amgen's Anemia Drug Aranesp Is Safe Before Kidney Dialysis, FDA Panel Says - Bloomberg PDF Print
BloombergEliminating pre- dialysis use may shave $200 million to $400 million from Amgen's annual sales, or 5 to 10 cents from per-share earnings, said Michael Yee,

... read more

 
Share |
Copyright © 2026 Global Dialysis. All Rights Reserved.